A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Pyrimethamine (Daraprim)

Dihydrofolate Reductase Inhibitor Antimalarial class · 3 generic manufacturers · 3 ANDAs filed at FDA.

First FDA approval1953-01-23
Generic availableYes · 3 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$11.6M in CY2024 Part D spend803 claims · 205 beneficiaries · 329 plans surveyed

Lowest NADAC
$137.01/unit
6 NDCs benchmarked, lowest of all strengths.
Average NADAC
$137.01
Across all dosage forms in distribution.
Highest NADAC
$137.01
Range is tight.
Plans with PA
280 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema10 entries indexed · 4 visible
What is Pyrimethamine used for?

Pyrimethamine is a Dihydrofolate Reductase Inhibitor Antimalarial medication tracked in Medicare Part D.

Is there a generic for Pyrimethamine?

Yes. 3 ANDAs filed at FDA, 3 generic manufacturers currently shipping.

How much does my plan pay for Pyrimethamine?

Across 329 Part D plans, Pyrimethamine averages $137.01/unit (NADAC). Lowest available: $137.01/unit. Highest in distribution: $137.01/unit.

Is Pyrimethamine on the FDA shortage list?

No. Pyrimethamine is not currently on the FDA Drug Shortage Database.

6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (4 approvals on file) · NADAC unit costs: CMS NADAC weekly file (6 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.